for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Breakingviews

Breakingviews TV: Bold and big

Posted

AstraZeneca will pay $39 bln for U.S. biotech Alexion, which makes treatment for a rare immune disease. Competition and a wayward M&A strategy have depressed the target’s stock. As Neil Unmack argues, that’s both a threat and an opportunity for the UK group’s CEO Pascal Soriot.

Breakingviews

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up